Recommendations for the management of autoinflammatory diseases. - Wikidata - awgldk - TriplyDB

Recommendations for the management of autoinflammatory diseases.

Recommendations for the management of autoinflammatory diseases.

http://www.wikidata.org/entity/Q38537504

about

Mevalonate kinase deficiency: current perspectives Natural history of mevalonate kinase deficiency: a literature review Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Review of autoinflammatory diseases, with a special focus on periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review Novel mutation identified in severe early-onset tumor necrosis factor receptor-associated periodic syndrome: a case report Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.Febrile infection-related epilepsy syndrome treated with anakinra Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene.Pharmacological treatment options for cryopyrin-associated periodic syndromes.Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.Inflammasomes and dermatology.The burgeoning field of innate immune-mediated disease and autoinflammation.International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.Dermatologic Manifestations of Monogenic Autoinflammatory Diseases.Muckle-Wells syndrome in Chinese patients: a single center case series.Interleukin-1 Blockade: An Update on Emerging Indications.Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.Autoinflammatory Diseases with Periodic Fevers.[Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2)].Clinical update on inflammasomopathies.Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.TRAPPED - an insight into two sisters' struggle to access treatment for a rare genetic disease.Alterations in nucleotide-binding oligomerization domain-2 expression, pathway activation, and cytokine production in Yao syndrome.The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study.Polymyalgia rheumatica: an autoinflammatory disorder?Tocilizumab for the Treatment of Mevalonate Kinase Deficiency

P2860

Q26738667-B3D414BD-9063-49C7-810D-2A2376CDC72D Q26753055-D1EA7250-627B-41D7-A5DD-7367CC5FE389 Q28066193-8B22E31C-34CE-4811-B3FC-FE5D3F05B168 Q28066401-796C6A03-4AFD-40EB-A445-C0002AAF773C Q28066948-1C71E4CD-BE1D-40B2-9B52-CE810BF66F3E Q33587432-756052B1-ED2F-4163-9983-11C66E86334E Q36990716-F9282C02-F4F7-4F71-A654-AD42F66F849C Q37579506-70336510-3FE9-4EC2-806A-0E94D788EE98 Q37721228-E0B41A15-014A-49C5-9EEF-5FD1E21791D7 Q38674213-5AC7C9C9-1E50-4C14-B4E8-1A9443BF983F Q38697343-8C3355FE-8ADD-4E02-A858-56AC5AAC17F8 Q38797090-E34B8189-58B9-45FD-80A1-2C7F5B4C4F05 Q38967233-70710B78-C217-4542-A06C-C620BF422CE7 Q38977041-6FD64A2F-6CBB-44B4-B9CC-672133C4C2E6 Q38993829-D516684A-8527-49B3-9D4B-7577F280B629 Q39016299-FA161E63-46A3-48B0-8A39-AD283AE5E296 Q39021328-FE30A6BA-308F-432A-AFDA-ADA2495FF9E4 Q39060058-65F5684D-A39E-421E-BABA-846E2550F99B Q39301613-111763A4-D960-40D2-BBD8-5E20F78F22AF Q39301708-A7352D26-16C9-4E53-AEEF-C43268019959 Q39325689-76276CA0-0967-47B8-9C2F-63ABAEB6F30D Q39384980-6AD5895C-690A-4981-B833-24476D448058 Q40053587-288DF5BA-2D4D-479E-892D-BC8E811BD8BC Q40062051-08AD0CA0-4B17-4EDE-BA2B-31FD7CA1DB8C Q47306597-BB0DF4A7-7671-4CB3-A87D-3C36A53FA4F8 Q50152542-EC8E75AF-298E-4C5B-AE94-9BEDA9D13EBD Q50351105-AA73DDE7-824B-4E22-8884-2636BA02D3DF Q52689523-2FAE77EB-4005-4E4C-A9C6-FC1A1E52EC77 Q54251597-B0A13B0D-79AC-4419-AE6A-C26A2D01939A Q54945833-4950B33E-6623-4F1C-A33E-555189BB0EED Q55378273-DDA93CAA-A381-42F8-9E06-DF47E09FA608 Q58702054-7C379CE8-458B-4885-92AA-BFE610629306

P2860

Recommendations for the management of autoinflammatory diseases.

http://www.wikidata.org/entity/Q38537504

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Recommendations for the management of autoinflammatory diseases.

@en

type

label

Recommendations for the management of autoinflammatory diseases.

@en

prefLabel

Recommendations for the management of autoinflammatory diseases.

@en

P1433

Q38537504-A02E6B15-730F-4B9D-A52F-58237226B124

P1476

Q38537504-F84EFA9E-A019-4FE6-9C26-7B73DA57709E

P2093

Q38537504-02BCEF20-96F8-4274-81BF-899A2C13BEF3

Q38537504-03396898-6D6D-4D00-B954-9906875F7128

Q38537504-153D297C-A4E1-401F-824E-D2873DD4D7C0

Q38537504-1E6E1CB8-A977-42B6-8A75-BF42258A9B5F

Q38537504-319C8EC9-CA06-4B59-9716-A41BB80BDDAA

Q38537504-6CD30303-B1EC-4102-A2AF-5DDC4DE0A20D

Q38537504-8CDADADC-0D04-4E24-9275-DE1CC55459C1

Q38537504-A497C668-EC8F-447A-B04B-9691F8D96680

Q38537504-AA504038-6B81-4516-ABFD-AD84EA324E5F

Q38537504-AB0AC78D-6F0A-412A-9DD5-BA77910AA72B

P2860

Q38537504-04A06E49-0FBE-467D-B6AF-6AEF8ECCF051

Q38537504-04A937C5-91D5-49D5-B42D-320A902DC9F6

Q38537504-05001B01-A2D4-4200-8A4F-873B2AC0C2E2

Q38537504-05F93A46-AA4A-4654-8A66-2244EE041419

Q38537504-0958CBB1-7E03-48BF-88D7-1081AD2E737E

Q38537504-0D063FBB-5190-4FDC-8C4C-430968ED01C1

Q38537504-0F22EBD4-0450-4D0D-86FA-2BE82CD7919D

Q38537504-10D04EF4-B725-4C9F-924F-14C3C8C74F05

Q38537504-1E4394DC-0F1F-4E81-B778-16F04C7D4A57

Q38537504-21C4D7D5-FF97-4F44-9AD7-ACD67699E7E0

P304

Q38537504-39672764-3AEC-49F7-84FF-690C3E78207E

P31

Q38537504-38AD53D4-D76E-428D-A085-53E902ED32F9

P356

Q38537504-FA20443A-BD42-496F-9D3A-D1593C04521B

P407

Q38537504-E716070F-FEE4-461F-A6DD-DEAE9764839B

P433

Q38537504-D126E782-B4E3-49DF-8266-43374C817C41

P478

Q38537504-95D181C4-C2FB-457E-9654-13A6312F4FF7

P50

Q38537504-2FCB0DDD-7FB2-4DFB-9384-73F512848A50

Q38537504-4C9DFD70-5290-40FC-80B1-D727D79D2356

Q38537504-B3BAD4A3-7216-4D71-B460-39DA1F14B54C

Q38537504-BE8F2AA1-93A7-4853-9641-18AAB188667C

Q38537504-C2D57858-C6F8-46CA-8339-F539D8A3E6AA

Q38537504-CF219C4A-0B19-412A-83F8-75F788BD2263

Q38537504-F73349DE-EE9D-491C-86B8-6A7DD00F90D9

P577

Q38537504-84A88E87-8AD4-4E41-9DB5-558A9F2424EB

P5875

Q38537504-6DAF6056-FFAE-4770-B8CD-B8F2BBB7A8FB

P698

Q38537504-01C73392-A248-47B0-B69A-7514C0668AB9

P356

ANNRHEUMDIS-2015-207546

P1433

Annals of the Rheumatic Diseases

P1476

Recommendations for the management of autoinflammatory diseases

@en

P2093

Brian M Feldman

http://www.w3.org/2001/XMLSchema#string

Caroline Galeotti

http://www.w3.org/2001/XMLSchema#string

Gilles Grateau

http://www.w3.org/2001/XMLSchema#string

Huri Ozdogan

http://www.w3.org/2001/XMLSchema#string

Isabelle Kone-Paut

http://www.w3.org/2001/XMLSchema#string

Jasmin B Kuemmerle-Deschner

http://www.w3.org/2001/XMLSchema#string

Jerold Jeyaratnam

http://www.w3.org/2001/XMLSchema#string

Joost Frenkel

http://www.w3.org/2001/XMLSchema#string

Karyl S Barron

http://www.w3.org/2001/XMLSchema#string

Marco Gattorno

http://www.w3.org/2001/XMLSchema#string

P2860

The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference.

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

Cryopyrinopathies: update on pathogenesis and treatment.

MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes

P304

1636-1644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2015-207546

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Nienke M ter Haar

Helen J Lachmann

P577

2015-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279303921

http://www.w3.org/2001/XMLSchema#string

P698

26109736

http://www.w3.org/2001/XMLSchema#string